Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nakamae H, Storer B, Sandmaier BM, Maloney DG, Davis C, Corey L et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: Impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011; 96: 1838–1845.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 2004; 33: 419–423.

    Article  CAS  PubMed  Google Scholar 

  3. First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM . Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndrome. Blood 1985; 65: 368–374.

    CAS  PubMed  Google Scholar 

  4. Nash RA, Gooley T, Davis C, Appelbaum FR . The problem of thrombocytopenia after hematopoietic stem cell transplantation. Stem Cells 1996; 14 (Suppl 1): 261–273.

    Article  PubMed  Google Scholar 

  5. Dominietto A, Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Berisso G et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112: 219–227.

    Article  CAS  PubMed  Google Scholar 

  6. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 154–162.

    Article  CAS  PubMed  Google Scholar 

  7. Seber A, Shu XO, Defor T, Sencer S, Ramsay N . Risk factors for severe hemorrhagic cystitis following Bone marow transplantation. Bone Marrow Transplant 1999; 23: 35–40.

    Article  CAS  PubMed  Google Scholar 

  8. Trotman J, Nivison-Smith I, Dodds A . Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration. Bone Marrow Transplant 1999; 23: 797–801.

    Article  CAS  PubMed  Google Scholar 

  9. Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol. Blood Marrow Transplant 2014; 20: 382–386.

    Article  CAS  PubMed  Google Scholar 

  10. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404–409.

    Article  CAS  PubMed  Google Scholar 

  11. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116: 3163–3170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by educational grants from the ‘Association for Training, Education and Research in Hematology, Immunology and Transplantation’ (ATERHIT). We also thank the ‘Association pour la Recherche sur le Cancer (ARC)’, the ‘Fondation de France’, the ‘Fondation contre la Leucémie’, the ‘Agence de Biomédecine’, the ‘Association Cent pour Sang la Vie’, the ‘Association Laurette Fugain’, the ‘IRGHET’ and the ‘Ligue Contre le Cancer’ (Comités Grand-Ouest), for their generous and continuous support to our clinical and basic research work. Our transplant programs are supported by several grants from the French National Cancer Institute. We are grateful to Professor Junia V Melo (University of Adelaide, Australia, and Imperial College, London) for medical editing of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G Battipaglia.

Ethics declarations

Competing interests

The authors declare no conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Battipaglia, G., Ruggeri, A., Brissot, E. et al. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant 50, 1574–1577 (2015). https://doi.org/10.1038/bmt.2015.182

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.182

This article is cited by

Search

Quick links